Outlook on the Worldwide Fragment-based Drug Discovery Industry to 2030 - Featuring 2bind, Charles River Laboratories & ChemAxon Among Others - ResearchAndMarkets.com

DUBLIN--()--The "Fragment-based Drug Discovery Market: Library and Service Providers, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

This report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of this approach over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.

Drug discovery and development is a complex and tedious process that requires a significant amount of resources and capital investment (~USD 2.6 billion). In fact, on an average, the journey from the establishment of initial proof-of-concept to commercial launch, is estimated to take around 10-12 years. However, only a small fraction of early stage therapeutic candidates are able to make it past preclinical testing, into clinical evaluation. Further, even fewer clinical stage candidates are eventually approved for commercialization.

Given the growing complexity in drug discovery research, the overall expenditure on pharmaceutical / biotechnology R&D has steadily increased over time. Specifically, in 2019, R&D spending was estimated to be around USD 182 billion, with more than 16,000 drug molecules evaluated during the course of the whole year. The industry is presently under tremendous pressure to not only identify ways to mitigate the risks of failure of drug discovery programs, but also to meet the expectations / medical needs of a growing patient population.

Despite its many advantages, high-throughput screening (HTS) is an expensive process and pharmacological leads generated via this process have been associated with high attrition rates during preclinical development. In addition, this approach is also limited in terms of the number of compounds that can be developed and stored in compound libraries. Fragment-based drug discovery (FBDD), is a relatively new hit screening approach. which has been shown to offer a number of benefits, including a cost advantage and the potential to enable the generation of hits with improved physiochemical properties, over HTS. In this context, it is worth highlighting that three marketed drugs, namely Vemurafenib (ZELBORAF), Venetoclax (VENCLEXTA), and Erdafitinib (BALVERSA), originated from fragment-based library screens.

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview

3.2. Overview of Drug Development

3.3. Drug Discovery Process

3.4. High-Throughput Screening (HTS) and its Limitations

3.5. Fragment-based Drug Discovery (FBDD)

3.6. Challenges Related to FBDD

3.7. Future Perspectives

4. CURRENT MARKET LANDSCAPE

4.1. Chapter Overview

4.2. Fragment-based Drug Discovery: List of Library and Service Providers

4.3. Fragment-based Drug Discovery: List of Libraries and Technologies

5. COMPANY PROFILES: FRAGMENT-BASED DRUG DISCOVERY LIBRARY AND SERVICE PROVIDERS

5.1. Chapter Overview

5.2. 2bind

5.3. Charles River Laboratories

5.4. ChemAxon

5.5. ComInnex

5.6. Creative Biolabs

5.7. Creative Biostructure

5.8. CRELUX

5.9. Domainex

5.10. Evotec

5.11. Red Glead Discovery

5.12. SARomics Biostructures

5.13. Shanghai ChemPartner

5.14. Sygnature Discovery

5.15. Vernalis Research

6. PARTNERSHIPS AND COLLABORATIONS

6.1. Chapter Overview

6.2. Partnership Models

6.3. Fragment-based Drug Discovery Services Market: List of Partnerships and Collaborations

7. KEY ACQUISITION TARGETS

7.1. Chapter Overview

7.2. Scope and Methodology

7.3. Scoring Criteria and Key Assumptions

7.4. Potential Strategic Acquisition Targets in North America

7.5. Potential Strategic Acquisition Targets in Europe

7.6. Potential Strategic Acquisition Targets in Asia-Pacific

7.7. Concluding Remarks

8. COMPANY COMPETITIVENESS ANALYSIS

8.1. Chapter Overview

8.2. Methodology

8.3. Key Parameters

8.4. Competitiveness Analysis: Fragment-based Drug Discovery Library and Service Providers

9. COST SAVING ANALYSIS

9.1. Chapter Overview

9.2. Key Assumptions and Parameters

9.3. Methodology

9.4. Overall Cost Saving Potential Associated with FBDD, 2020-2030

9.5. Concluding Remarks

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS

10.1. Chapter Overview

10.2. Key Assumptions and Forecast Methodology

10.3. Global Fragment-based Drug Discovery Market, 2020-2030

10.4. Global Fragment-based Drug Discovery Market: Distribution by Type of Technique, 2020 and 2030

10.5. Global Fragment-based Drug Discovery Market: Distribution by Type of Service, 2020 and 2030

10.6. Global Fragment-based Drug Discovery Market: Distribution by End User, 2020 and 2030

10.7. Global Fragment-based Drug Discovery Market: Distribution by Geography, 2020 and 2030

11. EXECUTIVE INSIGHTS

12. CONCLUDING REMARKS

13. APPENDIX 1: TABULATED DATA

Companies Mentioned

  • 2bind
  • Accelero Biostructures
  • Advanced Chemistry Development (ACD / Labs)
  • Agilent Technologies
  • Allesh Biosciences Labs
  • Altaris Capital Partners
  • Astex Pharmaceuticals
  • AstraZeneca
  • Aunova Medchem
  • Aurora Fine Chemicals
  • Axxam
  • Basilea Pharmaceutica
  • Beactica
  • Bellvitge Biomedical Research Institute (IDIBELL)
  • BioAscent
  • BioBlocks
  • BioPredict
  • BioSolveIT
  • BOC Sciences
  • Boehringer Ingelheim
  • Bruker
  • C4X Discovery
  • Cambridge Crystallographic Data Centre
  • Cambridge MedChem Consulting
  • Carna Biosciences
  • Center for Drug Design and Discovery
  • Centre for Chemical Biology and Therapeutics
  • Charles River Laboratories
  • CHDI Foundation
  • ChemAxon
  • ChemBridge
  • ChemDiv
  • Chemical Computing Group
  • Collaborative Drug Discovery
  • Collidion
  • Columbia University
  • ComInnex
  • Conifer Point
  • CreaGen
  • Creative Biolabs
  • Creative Biostructure
  • CRELUX
  • Creoptix
  • Cresset
  • CrystalsFirst
  • Daiichi Sankyo
  • Danaher
  • Diamond Light Source
  • And Many More Companies!

For more information about this report visit https://www.researchandmarkets.com/r/2q10dy

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900